What is Citigroup's price target for TVTX?

Citigroup's latest stated price target for Travere Therapeutics Inc. (TVTX) is $48, from its action on Oct 31, 2025.

What is Citigroup's rating on TVTX?

Citigroup rates TVTX Buy, a bullish rating, as of Oct 31, 2025.

When did Citigroup last change its view on TVTX?

On Oct 31, 2025, Citigroup raises its price target to $48 from $34, keeps Buy.

Citigroup TVTX price target and rating history

Travere Therapeutics Inc. (TVTX) · Health Care

Citigroup rates Travere Therapeutics Inc. (TVTX) Buy with a $48 price target, as of its latest action on Oct 31, 2025. It has published 4 rating actions on TVTX since November 2023, including 1 upgrade and 0 downgrades.

Current rating: Buy
Price target: $48
Median target, all firms: Too few
Actions on TVTX: 4

Citigroup price target on TVTX

Citigroup price target on TVTX, each point a stated target, November 2023 to October 2025.

Every Citigroup rating on TVTX

Oct 31, 2025
ReiterateCitigroup raises its price target to $48 from $34, keeps Buy
Jun 11, 2025
ReiterateCitigroup cuts its price target to $32 from $35, keeps Buy
Dec 5, 2023
UpgradeCitigroup upgrades to Buy from Neutral, price target $7 to $10
Nov 20, 2023
InitiateCitigroup starts coverage at Neutral, price target $7

Questions about Citigroup and TVTX

What is Citigroup's price target for TVTX?: Citigroup's latest stated price target for Travere Therapeutics Inc. (TVTX) is $48, from its action on Oct 31, 2025.
What is Citigroup's rating on TVTX?: Citigroup rates TVTX Buy, a bullish rating, as of Oct 31, 2025.
When did Citigroup last change its view on TVTX?: On Oct 31, 2025, Citigroup raises its price target to $48 from $34, keeps Buy.

More TVTX rating histories

All Citigroup ratings TVTX news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.